Biotech · Public company · Cambridge, MA, US

Foghorn Therapeutics Inc.

Ticker FHTX · SEC CIK 0001822462

Track this companyFree. Adds Foghorn Therapeutics Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials53 recruiting or active

Pipeline programs5From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline5

DecitabinePhase 1 · Advanced Hematologic MalignancyClinicalTrials.gov · fetched Nov 12, 2026
FHD-286Phase 1 · Advanced Hematologic MalignancyClinicalTrials.gov · fetched Nov 12, 2026
FHD-286Phase 1 · Metastatic Uveal MelanomaClinicalTrials.gov · fetched Nov 12, 2026
FHD-609Phase 1 · Advanced Synovial SarcomaClinicalTrials.gov · fetched Nov 12, 2026
Low Dose CytarabinePhase 1 · Advanced Hematologic MalignancyClinicalTrials.gov · fetched Nov 12, 2026

SMARCA4/2 Inhibitor for POU2F3-Positive SCLCPHASE2 · RECRUITING · started Apr 28, 2026ClinicalTrials.gov NCT07551635 · fetched Nov 12, 2026
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid LeukemiaPHASE1 · RECRUITING · started Feb 3, 2026ClinicalTrials.gov NCT07283094 · fetched Nov 12, 2026
FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss TumorsPHASE1 · TERMINATED · started Aug 17, 2021ClinicalTrials.gov NCT04965753 · fetched Nov 12, 2026
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic MalignanciesPHASE1 · ACTIVE_NOT_RECRUITING · started Jun 14, 2021ClinicalTrials.gov NCT04891757 · fetched Nov 12, 2026
FHD-286 in Subjects With Metastatic Uveal MelanomaPHASE1 · TERMINATED · started May 11, 2021ClinicalTrials.gov NCT04879017 · fetched Nov 12, 2026